Target Attainment of Cefuroxim
Launched by NOORDWEST ZIEKENHUISGROEP · Jan 7, 2022
Trial Information
Current as of May 06, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Receiving cefuroxime therapy intravenous (iv) as part of standard care
- • Age ≥ 18 years
- • Admitted to a general ward of Noordwest Ziekenhuisgroep - location Alkmaar
- • Informed consent is obtained
- Exclusion Criteria:
- • Mentally incapacitated patients, i.e. a minor or legally incompetent adult
- • Renal replacement therapy during treatment with cefuroxime
- • Patients admitted to the intensive care unit (ICU)
- • Severely burned patients, defined as a burned surface ≥ 10%
- • Patients with cystic fibrosis
- • Informed consent is not obtained
About Noordwest Ziekenhuisgroep
Noordwest Ziekenhuisgroep is a leading healthcare institution in the Netherlands, dedicated to providing high-quality patient care and advancing medical research through innovative clinical trials. With a commitment to improving health outcomes, the organization fosters collaboration among multidisciplinary teams to explore new treatment options and enhance existing therapies. Noordwest Ziekenhuisgroep emphasizes ethical standards and patient safety in all its research endeavors, ensuring that clinical trials are conducted with the utmost rigor and adherence to regulatory guidelines. Through its research initiatives, the institution aims to contribute significantly to the medical community and improve the lives of patients both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Alkmaar, Noord Holland, Netherlands
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials